<DOC>
	<DOCNO>NCT01841281</DOCNO>
	<brief_summary>The major impact study identify adult severe asthma cohort benefit supplemental L-arginine therapy . The investigator hypothesize subset adult severe asthma patient respond supplemental L-arginine derive clinical benefit addition therapy standard-of-care asthma medication . The investigator hypothesize patient benefit low exhale nitric oxide concentration ( &lt; 20 ppb ) baseline .</brief_summary>
	<brief_title>L-arginine Severe Asthma Patients Grouped Exhaled Nitric Oxide Levels</brief_title>
	<detailed_description>We hypothesize subset adult severe asthma patient respond supplemental L-arginine derive clinical benefit addition therapy standard-of-care medication . We hypothesize patient low exhale NO concentration ( &lt; 20 ppb ) low nitric oxide synthase 2 ( NOS2 ) / arginase I ( Arg1 ) mRNA ratio airway epithelial cell `` non-responders . '' The aim test hypothesis adult severe asthma subject exhale breath NO concentration &lt; 20 ppb few American Thoracic Society ( ATS ) -defined asthma exacerbation 3 month treat L-arginine compare subject exhale nitric oxide concentration ( FeNO ) &gt; 25 ppb . The major impact study identify adult severe asthma cohort benefit supplemental L-arginine therapy define underlie mechanism arginine benefit asthma . This follow initial 20 subject trial L-arginine asthma subject ( Kenyon et al. , Pharmaceuticals 2011 ) design determine L-arginine metabolize ( test serum marker ) whether certain participant clinical benefit . To , recruit total 50 ATS-defined severe asthmatic subject ongoing asthma exacerbation past two month enroll randomize , blind , placebo-controlled , cross-over design trial L-arginine placebo . We compare 25 subject `` low '' FeNO &lt; 20 25 subject `` high '' FeNO &gt; 25 ppb .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Adults &gt; 18 yrs age Diagnosis severe asthma base American Thoracic Society Workshop definition ( Am J Respir Crit Care Med 2000 ; 162:2341 ) Active asthma medication high dose inhaled corticosteroid plus longacting beta agonist History recent asthma exacerbation Asthma control test score &lt; 20/25 &lt; 19 yr age Forced expiratory volume 1sec &lt; 30 % predict Pregnant nurse woman Current smoker smoke history &gt; 15 pack year Actively take know intolerance Larginine</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Severe Asthma</keyword>
</DOC>